GeoVax Develops COVID-19 Vaccine With Superior T-Cell Response
GeoVax has developed a breakthrough COVID-19 vaccine demonstrating superior T-cell responses, particularly for immunocompromised patients. The vaccine achieved a 40% endpoint success rate, significantly higher than the 14.3% seen with existing vaccines.
Topics
Developing
- 862d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 862d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 862d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 862d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
Source Alpha
Source Bravo
Source Charlie
Source Delta
Source Echo
Source Foxtrot
Source Golf
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade